LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 61

Search options

  1. Article ; Online: Identifying thresholds for clinically meaningful change among clients of drug and alcohol services using the Australian Treatment Outcomes Profile.

    Deacon, Rachel M / Mills, Llewellyn / Bruno, Raimondo / Mammen, Kristie / Dunlop, Adrian / Childs, Steven / Shakeshaft, Anthony / Holmes, Jennifer / Lintzeris, Nicholas

    Addiction (Abingdon, England)

    2023  Volume 118, Issue 12, Page(s) 2457–2465

    Abstract: Aims: The Austraian Treatment Outcomes Profile (ATOP) is a brief clinical outcomes tool used widely in the Australian alcohol and other drugs treatment sector to monitor clients' substance use, health, wellbeing and clinical risk factors. It has ... ...

    Abstract Aims: The Austraian Treatment Outcomes Profile (ATOP) is a brief clinical outcomes tool used widely in the Australian alcohol and other drugs treatment sector to monitor clients' substance use, health, wellbeing and clinical risk factors. It has demonstrated reliability and validity, and has recommended clinical cut-offs for assessing single-occasion client-rated health scores. This study determined clinically meaningful change thresholds for ATOP substance use and health and wellbeing variables for use by clinicians in monitoring client progress, and for quality improvement and service evaluation.
    Design, setting and participants: A framework for assessing clinically meaningful changes scores was developed by (1) calculating statistically reliable change thresholds using data-driven techniques with a reference sample of clinical ATOP data and (2) conducting a multi-disciplinary subject matter expert group to review the utility and validity of data-derived clinically meaningful change. The study was conducted within Outpatient Alcohol and Other Drug treatment services in New South Wales, Australia. The reference sample comprised 6100 ATOPs from clients at entry to public outpatient Alcohol and Other Drug treatment services; the subject matter expert group comprised 29 key stakeholders from the specialist alcohol and other drug treatment sector.
    Measurements and findings: We used the Reliable Change Index method to calculate clinically meaningful change thresholds for ATOP variables. For substance use variables, a change of 30% in days of use in the last 28 (minimum 4 days) was the threshold for clinically meaningful change for substance use; for health and wellbeing variables, a change of 2 or more points in psychological health, physical health or quality of life scores (measured on 0-10 scales) was the minimum clinically meaningful change.
    Conclusions: Clinically meaningful change thresholds have been proposed for Australian Treatment Outcomes Profile substance use and health and wellbeing items, based on statistical reliability and subject matter expert assessment. These will be used in the development of an outcomes metric for assessing change and assigning meaning in aggregated data for evaluation of services.
    MeSH term(s) Humans ; Australia ; Quality of Life ; Reproducibility of Results ; Substance-Related Disorders/therapy ; Substance-Related Disorders/psychology ; Treatment Outcome
    Language English
    Publishing date 2023-07-08
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1141051-6
    ISSN 1360-0443 ; 0965-2140
    ISSN (online) 1360-0443
    ISSN 0965-2140
    DOI 10.1111/add.16295
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides

    Llewellyn, George Nicholas / Chen, Hsu-Yu / Rogers, Geoffrey L. / Huang, Xiaoli / Sell, Philip / Henley, Jill E / Cannon, Paula M.

    bioRxiv

    Abstract: With increasing resistance of SARS-CoV-2 variants to antibodies, there is interest in developing entry inhibitors that target essential receptor binding regions of the viral Spike protein and thereby present a high bar for viral resistance. Such ... ...

    Abstract With increasing resistance of SARS-CoV-2 variants to antibodies, there is interest in developing entry inhibitors that target essential receptor binding regions of the viral Spike protein and thereby present a high bar for viral resistance. Such inhibitors can be derivatives of the viral receptor, ACE2, or peptides engineered to interact specifically with the receptor-binding pocket. We compared the efficacy of a series of both types of entry inhibitors, constructed as fusions to an antibody Fc domain. Such a design can increase protein stability and act to both neutralize free virus and recruit effector functions to clear infected cells. We tested the reagents against prototype variants of SARS-CoV-2, using both Spike pseudotyped VSV vectors and viral plaque assays. These analyses revealed that an optimized ACE2 derivative could neutralize all variants we tested with high efficacy. In contrast, the Spike-binding peptides had varying activities against different variants, with resistance observed for the Spike proteins from Beta, Gamma and Omicron. The resistance mapped to mutations at Spike residues K417 and N501 and could be overcome for one of the peptides by linking two copies in tandem, effectively creating a tetrameric reagent in the Fc fusion. Finally, both the optimized ACE2 and tetrameric peptide inhibitors provided some protection to human ACE2 transgenic mice challenged with the SARS-CoV-2 Delta variant, which typically causes death in this model within 7-9 days.
    Keywords covid19
    Language English
    Publishing date 2023-01-06
    Publisher Cold Spring Harbor Laboratory
    Document type Article ; Online
    DOI 10.1101/2023.01.05.522964
    Database COVID19

    Kategorien

  3. Article ; Online: Substance use, socio-demographic characteristics, and self-rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study.

    Black, Emma / Bruno, Raimondo / Mammen, Kristie / Mills, Llewellyn / Siefried, Krista J / Deacon, Rachel M / Shakeshaft, Anthony / Dunlop, Adrian J / Ezard, Nadine / Montebello, Mark / Childs, Steven / Reid, David / Holmes, Jennifer / Lintzeris, Nicholas

    The Medical journal of Australia

    2023  Volume 219, Issue 5, Page(s) 218–226

    Abstract: Objective: To investigate the demographic characteristics, substance use, and self-rated health of people entering treatment in New South Wales public health services for alcohol, amphetamine-type stimulants, cannabis, cocaine, or opioids use, by ... ...

    Abstract Objective: To investigate the demographic characteristics, substance use, and self-rated health of people entering treatment in New South Wales public health services for alcohol, amphetamine-type stimulants, cannabis, cocaine, or opioids use, by principal drug of concern.
    Design: Baseline findings of a cohort study; analysis of data in patient electronic medical records and NSW minimum data set for drug and alcohol treatment services.
    Setting, participants: People completing initial Australian Treatment Outcomes Profile (ATOP) assessments on entry to publicly funded alcohol and other drug treatment services in six NSW local health districts/networks, 1 July 2016 - 30 June 2019.
    Main outcome measures: Socio-demographic characteristics, and substance use and self-rated health (psychological, physical, quality of life) during preceding 28 days, by principal drug of concern.
    Results: Of 14 087 people included in our analysis, the principal drug of concern was alcohol for 6051 people (43%), opioids for 3158 (22%), amphetamine-type stimulants for 2534 (18%), cannabis for 2098 (15%), and cocaine for 246 (2%). Most people commencing treatment were male (9373, 66.5%), aged 20-39 years (7846, 50.4%), and were born in Australia (10 934, 86.7%). Polysubstance use was frequently reported, particularly by people for whom opioids or amphetamine-type stimulants were the principal drugs of concern. Large proportions used tobacco daily (53-82%, by principal drug of concern group) and reported poor psychological health (47-59%), poor physical health (32-44%), or poor quality of life (43-52%).
    Conclusions: The prevalence of social disadvantage and poor health is high among people seeking assistance with alcohol, amphetamine-type stimulants, cannabis, cocaine, or opioids use problems. Given the differences in these characteristics by principal drug of concern, health services should collect comprehensive patient information during assessment to facilitate more holistic, tailored, and person-centred care.
    MeSH term(s) Humans ; Male ; Female ; New South Wales/epidemiology ; Cohort Studies ; Analgesics, Opioid/therapeutic use ; Quality of Life ; Australia/epidemiology ; Substance-Related Disorders/epidemiology ; Substance-Related Disorders/therapy ; Amphetamine ; Central Nervous System Stimulants ; Ethanol ; Cannabis ; Cocaine
    Chemical Substances Analgesics, Opioid ; Amphetamine (CK833KGX7E) ; Central Nervous System Stimulants ; Ethanol (3K9958V90M) ; Cocaine (I5Y540LHVR)
    Language English
    Publishing date 2023-07-14
    Publishing country Australia
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 186082-3
    ISSN 1326-5377 ; 0025-729X
    ISSN (online) 1326-5377
    ISSN 0025-729X
    DOI 10.5694/mja2.52039
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The Overdose Response with Take Home Naloxone (ORTHN) project: Evaluation of health worker training, attitudes and perceptions.

    Monds, Lauren A / Bravo, Maria / Mills, Llewellyn / Malcolm, Annie / Gilliver, Rosie / Wood, William / Harrod, Mary Ellen / Read, Phillip / Nielsen, Suzanne / Dietze, Paul M / Lenton, Simon / Bleeker, Anne M / Lintzeris, Nicholas

    Drug and alcohol review

    2022  Volume 41, Issue 5, Page(s) 1085–1094

    Abstract: Introduction: Naloxone is a life-saving medication that reverses opioid overdose; naloxone can be provided on a 'take-home' basis so naloxone can be administered outside of the health-care setting. The Overdose Response and Take Home Naloxone (ORTHN) ... ...

    Abstract Introduction: Naloxone is a life-saving medication that reverses opioid overdose; naloxone can be provided on a 'take-home' basis so naloxone can be administered outside of the health-care setting. The Overdose Response and Take Home Naloxone (ORTHN) project established a model of care for take-home naloxone (THN) interventions across alcohol and other drug and harm reduction services in NSW, Australia. This paper evaluates the staff training and credentialing program, and examines staff attitudes and perspectives regarding the provision of THN interventions in these settings.
    Methods: Staff across seven services were trained through a 'train-the-trainer' credentialing model to deliver ORTHN, including naloxone supply. Staff were surveyed regarding their experience, attitudes and knowledge on THN prior to and after training, and after 6 months. At the 6 months follow up, staff were asked about the interventions they provided, barriers and enablers to uptake, and opinions regarding future rollout.
    Results: A total of 204 staff were trained and credentialed to provide the ORTHN intervention. Most (60%) were nurses, followed by needle syringe program workers and allied health/counsellors (32%). Linear and logistic regression analyses indicated that the training program was associated with significant improvements in staff knowledge and attitudes towards overdose and THN; however, only attitudinal improvements were maintained over time. There were high rates of staff satisfaction with the ORTHN intervention and training.
    Discussion/conclusions: The ORTHN program is 'fit for purpose' for broad implementation in these settings. A number of potential barriers (e.g. time, medication and staffing costs) and enablers (e.g. peer engagement, regulatory framework for naloxone supply) in implementing THN interventions were identified.
    MeSH term(s) Drug Overdose/drug therapy ; Harm Reduction ; Health Knowledge, Attitudes, Practice ; Humans ; Naloxone/therapeutic use ; Narcotic Antagonists/therapeutic use ; Opioid-Related Disorders/drug therapy
    Chemical Substances Narcotic Antagonists ; Naloxone (36B82AMQ7N)
    Language English
    Publishing date 2022-04-20
    Publishing country Australia
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1080442-0
    ISSN 1465-3362 ; 0959-5236
    ISSN (online) 1465-3362
    ISSN 0959-5236
    DOI 10.1111/dar.13474
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016-2019.

    Black, Emma / Mammen, Kristie / Deacon, Rachel M / Ezard, Nadine / Mills, Llewellyn / Dunlop, Adrian J / Montebello, Mark / Reid, David / Childs, Steven / Bruno, Raimondo / Shakeshaft, Anthony / Siefried, Krista J / Farrell, Michael / Holmes, Jennifer / Lintzeris, Nicholas

    Drug and alcohol review

    2022  Volume 42, Issue 2, Page(s) 389–400

    Abstract: Introduction: Amphetamine type substances (ATS) are commonly used by Australian alcohol and other drug service entrants. We describe demographic characteristics, patterns of ATS and other substance use, health and social conditions among clients ... ...

    Abstract Introduction: Amphetamine type substances (ATS) are commonly used by Australian alcohol and other drug service entrants. We describe demographic characteristics, patterns of ATS and other substance use, health and social conditions among clients entering New South Wales (NSW) public alcohol and other drug services.
    Methods: Retrospective cohort of 13,864 records across six health districts (2016-2019) for clients seeking substance use treatment. These districts service approximately 44% of the NSW population aged 15 years and over. Multivariate analysis was conducted on a subsample for whom full data were available (N = 9981). Data included NSW Minimum Data Set for drug and alcohol treatment services and Australian Treatment Outcomes Profile items.
    Results: Over the preceding 4 weeks, 77% (n = 10,610) of clients (N = 13,864) reported no recent ATS use, 15% (n = 2109) reported 'low frequency' (1-12 days) and 8% (n = 1145) 'high frequency' (13-28 days) use. ATS use was most common among people attending for ATS or opioids as primary drug of concern. A multinomial regression (N = 9981) identified that clients reporting recent arrest (aOR 1.74, 95% CI 1.36, 2.24), higher cannabis use frequency (aOR 1.01, 95% CI 1.00, 1.02), lower opioid use frequency (aOR 0.98, 95% CI 0.97, 0.99) and poorer quality of life (aOR 0.91, 95% CI 0.86, 0.97) were more likely to report 'high frequency' rather than 'low frequency' ATS use.
    Discussion and conclusions: People who use ATS experience health and social issues that may require targeted responses. These should be integrated across all services, not only for clients with ATS as principal drug of concern.
    MeSH term(s) Humans ; Australia/epidemiology ; New South Wales/epidemiology ; Amphetamine ; Quality of Life ; Retrospective Studies ; Ethanol ; Opioid-Related Disorders ; Sociological Factors
    Chemical Substances Amphetamine (CK833KGX7E) ; Ethanol (3K9958V90M)
    Language English
    Publishing date 2022-12-16
    Publishing country Australia
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1080442-0
    ISSN 1465-3362 ; 0959-5236
    ISSN (online) 1465-3362
    ISSN 0959-5236
    DOI 10.1111/dar.13588
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition.

    Mills, Llewellyn / Lintzeris, Nicholas / O'Malley, Michael / Arnold, Jonathon C / McGregor, Iain S

    Drug and alcohol review

    2022  Volume 41, Issue 5, Page(s) 1095–1108

    Abstract: Introduction: Prior research has examined the prevalence and correlates of cannabis use disorder (CUD) in people who use cannabis; however, these are poorly described for people using cannabis for medical reasons.: Methods: Data came from a 2018 to ... ...

    Abstract Introduction: Prior research has examined the prevalence and correlates of cannabis use disorder (CUD) in people who use cannabis; however, these are poorly described for people using cannabis for medical reasons.
    Methods: Data came from a 2018 to 2019 online, anonymous, cross-sectional survey of Australians reporting using either illicit or licit cannabis for medical reasons within the past year. Included were questions on demographics, current and lifetime patterns of cannabis use, clinical conditions for which medical cannabis was used, and individual criteria for CUD and cannabis withdrawal syndrome. Bayesian Horseshoe logistic regression models were used to identify covariates associated with meeting CUD DSM-5 conditions for any-CUD (≥2/11 criteria) and moderate-severe-CUD (≥4/11).
    Results: A total of 905 participants were included in the analysis. The majority (98%) used illicit cannabis products. Criteria for any-CUD criteria were met by 290 (32.0%), and 117 (12.9%) met criteria for moderate-severe-CUD. Tolerance (21%) and withdrawal (35%) were the most commonly met criteria. Correlates with the strongest association with CUD were inhaled route of administration [odds ratio (OR) = 2.96, 95% credible interval 1.11, 7.06], frequency of cannabis use (OR = 1.24, 1.11-1.35), proportion of cannabis for medical reasons (OR = 0.83, 0.74, 0.94), frequency of tobacco use (OR = 1.10, 1.03, 1.17), age (OR = 0.75, 0.64, 0.90) and pain as main clinical indication (OR = 0.58, 0.36, 1.00).
    Discussion and conclusions: Prevalence of CUD in medical cannabis users appears comparable to 'recreational' users, with many similar correlates. CUD was associated with using cannabis to treat mental health rather than pain conditions and inhaled over other routes of administration.
    MeSH term(s) Analgesics ; Australia/epidemiology ; Bayes Theorem ; Cannabis ; Cross-Sectional Studies ; Hallucinogens ; Humans ; Marijuana Abuse/epidemiology ; Medical Marijuana/therapeutic use ; Pain ; Prevalence ; Substance-Related Disorders
    Chemical Substances Analgesics ; Hallucinogens ; Medical Marijuana
    Language English
    Publishing date 2022-02-16
    Publishing country Australia
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1080442-0
    ISSN 1465-3362 ; 0959-5236
    ISSN (online) 1465-3362
    ISSN 0959-5236
    DOI 10.1111/dar.13444
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Chemoenzymatic acylation of aminoglycoside antibiotics.

    Llewellyn, Nicholas M / Spencer, Jonathan B

    Chemical communications (Cambridge, England)

    2008  , Issue 32, Page(s) 3786–3788

    Abstract: The chemoenzymatic installation of the clinically valuable (S)-4-amino-2-hydroxybutyryl side chain onto a number of 2-deoxystreptamine-containing aminoglycosides is described using the purified Bacillus circulans biosynthetic enzymes BtrH and BtrG in ... ...

    Abstract The chemoenzymatic installation of the clinically valuable (S)-4-amino-2-hydroxybutyryl side chain onto a number of 2-deoxystreptamine-containing aminoglycosides is described using the purified Bacillus circulans biosynthetic enzymes BtrH and BtrG in combination with a synthetic acyl-SNAC surrogate substrate.
    MeSH term(s) Acylation ; Aminoglycosides/chemical synthesis ; Anti-Bacterial Agents/chemical synthesis ; Bacterial Proteins/metabolism ; Butirosin Sulfate/chemical synthesis ; Butirosin Sulfate/pharmacology ; Indicators and Reagents ; Membrane Transport Proteins/metabolism ; Transaminases/metabolism
    Chemical Substances Aminoglycosides ; Anti-Bacterial Agents ; Bacterial Proteins ; ButB protein, Bacillus circulans ; Indicators and Reagents ; Membrane Transport Proteins ; Butirosin Sulfate (51022-98-1) ; BtrR aminotransferase, Bacillus circulans (EC 2.6.1.-) ; Transaminases (EC 2.6.1.-)
    Language English
    Publishing date 2008-08-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 1472881-3
    ISSN 1364-548X ; 1359-7345 ; 0009-241X
    ISSN (online) 1364-548X
    ISSN 1359-7345 ; 0009-241X
    DOI 10.1039/b802248h
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations.

    Deacon, Rachel M / Mammen, Kristie / Holmes, Jennifer / Dunlop, Adrian / Bruno, Raimondo / Mills, Llewellyn / Graham, Robert / Lintzeris, Nicholas

    Drug and alcohol review

    2020  Volume 39, Issue 5, Page(s) 441–446

    Abstract: Introduction and aims: The Australian Treatment Outcomes Profile (ATOP) is a brief clinical tool measuring recent substance use, health and wellbeing among clients attending alcohol and other drug (AOD) treatment services. It has previously been ... ...

    Abstract Introduction and aims: The Australian Treatment Outcomes Profile (ATOP) is a brief clinical tool measuring recent substance use, health and wellbeing among clients attending alcohol and other drug (AOD) treatment services. It has previously been assessed for concurrent validity and inter-rater reliability. In this study we examine whether it is suitable for administration over the telephone.
    Design and methods: We recruited a sample of 107 AOD clients across public sector specialist AOD treatment services in New South Wales, Australia between 2016 and 2018. Participants had a mean age of 47 years and 46% were female. Participants completed a face-to-face ATOP and a phone ATOP with a researcher within 5 days. Comparisons between the two administration modes were undertaken using Spearman's rank correlation coefficient for continuous or ordinal variables, and Cohen's Kappa for nominal variables.
    Results: Among 107 participants, 59% were attending for alcohol treatment and 41% for opioid treatment. Most ATOP items (76%) reached above 0.7 (good) or 0.9 (excellent) agreement between face-to-face and telephone use.
    Discussion and conclusions: Our findings suggest that the ATOP is a suitable instrument for telephone monitoring of recent substance use, health and social functioning among AOD clients. Its validation for remote use over the telephone will support staff to monitor clients' risks and outcomes-of particular relevance in response to the COVID-19 pandemic in which services are increasingly relying on telework approaches to client monitoring.
    MeSH term(s) Adult ; Alcoholism/rehabilitation ; Australia ; COVID-19 ; Coronavirus Infections/epidemiology ; Female ; Humans ; Male ; Middle Aged ; New South Wales ; Pandemics ; Pneumonia, Viral/epidemiology ; Reproducibility of Results ; Substance Abuse Treatment Centers/methods ; Substance-Related Disorders/rehabilitation ; Surveys and Questionnaires ; Telephone ; Treatment Outcome
    Keywords covid19
    Language English
    Publishing date 2020-05-12
    Publishing country Australia
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Validation Study
    ZDB-ID 1080442-0
    ISSN 1465-3362 ; 0959-5236
    ISSN (online) 1465-3362
    ISSN 0959-5236
    DOI 10.1111/dar.13088
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Biological chemistry: enzymes line up for assembly.

    Llewellyn, Nicholas M / Spencer, Jonathan B

    Nature

    2007  Volume 448, Issue 7155, Page(s) 755–756

    MeSH term(s) Anti-Bacterial Agents/biosynthesis ; Bacteria/enzymology ; Bacteria/genetics ; Bacteria/metabolism ; Catalysis ; Genes, Bacterial/genetics ; Multigene Family/genetics ; Peptide Synthases/chemistry ; Peptide Synthases/genetics ; Peptide Synthases/metabolism ; Polyenes/chemistry ; Polyenes/metabolism ; Pyrroles/chemistry ; Pyrroles/metabolism ; Transglutaminases/chemistry ; Transglutaminases/genetics ; Transglutaminases/metabolism
    Chemical Substances Anti-Bacterial Agents ; Polyenes ; Pyrroles ; andrimid (108868-95-7) ; Transglutaminases (EC 2.3.2.13) ; Peptide Synthases (EC 6.3.2.-)
    Language English
    Publishing date 2007-08-16
    Publishing country England
    Document type Comment ; News
    ZDB-ID 120714-3
    ISSN 1476-4687 ; 0028-0836
    ISSN (online) 1476-4687
    ISSN 0028-0836
    DOI 10.1038/448755a
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Determining clinical cutoff scores for the Australian Treatment Outcomes Profile psychological health, physical health and quality of life questions.

    Mammen, Kristie / Mills, Llewellyn / Deacon, Rachel M / Bruno, Raimondo / Dunlop, Adrian / Holmes, Jennifer / Luksza, Jennifer / Shakeshaft, Anthony / Farrell, Michael / Lintzeris, Nicholas

    Drug and alcohol review

    2021  Volume 41, Issue 1, Page(s) 106–113

    Abstract: Introduction: The Australian Treatment Outcomes Profile (ATOP) is a brief instrument that measures self-reported substance use, health, and wellbeing in the previous 28 days for people in alcohol and other drug treatment. Previous studies have ... ...

    Abstract Introduction: The Australian Treatment Outcomes Profile (ATOP) is a brief instrument that measures self-reported substance use, health, and wellbeing in the previous 28 days for people in alcohol and other drug treatment. Previous studies have established the concurrent validity, inter-rater, and test-retest reliability of the tool. The current study sought to identify recommended cutoff scores for ATOP items for psychological health, physical health and quality of life that identify clients reporting clinically significant problems warranting further assessment and/or intervention, compared to cutoffs used by 'gold-standard' measures for these domains.
    Methods: Clients attending for treatment for problems with opioid (n = 144) or alcohol use (n = 134) completed the ATOP and comparison standardised questionnaires (Kessler-10, Short Form Survey 12 and the Personal Wellbeing Index) with a researcher. Receiver operating characteristics analysis, along with clinician perspectives, were used to recommend cutoff scores for ATOP items indicative of clinically significant problems.
    Results: A cutoff score of 5 or less out of 10 was identified as an optimal pragmatic cutoff for ATOP items relating to psychological health, physical health and quality of life items with regards to balancing sensitivity, specificity, and application in a treatment setting.
    Discussion and conclusions: The recommended clinical cutoffs will support clinicians and treatment services to identify clients who require further assessment and follow up for their psychological health, physical health and quality of life. The current study provides further evidence for the utility of the ATOP for individual clinical review, service planning and research.
    MeSH term(s) Australia ; Humans ; Mental Health ; Psychometrics ; Quality of Life ; Reproducibility of Results ; Surveys and Questionnaires ; Treatment Outcome
    Language English
    Publishing date 2021-06-29
    Publishing country Australia
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1080442-0
    ISSN 1465-3362 ; 0959-5236
    ISSN (online) 1465-3362
    ISSN 0959-5236
    DOI 10.1111/dar.13346
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top